Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700942 | 0.75 | TDP1 (0.46) | TDP1HPGDADORA1ADORA2AELANE | |
| SCHEMBL16896543 | 0.73 | TDP1 (0.44) | TDP1HPGDELANERAB9A | |
| SCHEMBL24330410 | 0.73 | TDP1 (0.44) | TDP1HPGDELANE | |
| SCHEMBL880329 | 0.72 | GAA (0.66) | TDP1HPGDELANEKDM4EMEN1 | |
| SCHEMBL5533525 | 0.71 | HTR3A (0.43) | TDP1ELANEMEN1KMT2AMAPT | |
| SCHEMBL31490013 | 0.70 | TDP1 (0.41) | TDP1ELANEKMT2AALDH1A1LMNA | |
| SCHEMBL219441 | 0.69 | POLB (0.48) | TDP1HPGDKDM4ERAB9AGAA | |
| SCHEMBL12785091 | 0.69 | TDP1 (0.47) | TDP1HPGDELANEKDM4EKMT2A | |
| SCHEMBL22777815 | 0.69 | NR4A2 (0.46) | HPGDALDH1A1 | |
| SCHEMBL29448072 | 0.69 | NR4A2 (0.46) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814888-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | PFIZER INC | 2006-08-03 | — | — | US | disclosed |
| WO-2006051394-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | CHRNA7, CHRNA5, CHRNA10 | TDP1 1694/4885HPGD 2488/4885ADORA1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.